Home > Insider Trading > Filing (0000899243-21-039976)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1809519	Goodrx Holdings Inc.	GDRX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1632311	Bansi Nagji	C/O Goodrx Holdings, Inc. 2701 Olympic Boulevard Santa Monica CA 90404	President, Healthcare	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2021-10-07	3,600	$6.84	32,766	No	4	M	Direct
Class A Common Stock	Disposition	2021-10-07	3,600	$45.05	29,166	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Stock Option (Right to Buy)	Disposition	2021-10-07	3,600	$0.00	3,600	$6.84

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,600		2030-06-15	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.18. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option vested and became exercisable as to 25,000 shares on the closing date of the Issuer's initial public offering of securities, and vested or will vest as to 1/48th of the original 400,000 shares monthly thereafter until fully vested on June 10, 2024.
The Reporting Person's prior Form 4 filed on September 16, 2021 incorrectly stated that 309,564 shares underlying this option remained after the reported transactions and should have reported 309,584 shares underlying this option after the reported transactions.